(Q51722492)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147897%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Applying physiological and biochemical concepts to optimize biological drug development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147897%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147897%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

P J Lowe

series ordinal

1

1 reference

10 April 2018

http://europepmc.org/abstract/MED/20147897

language of work or name

English

0 references

publication date

10 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147897%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147897%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147897%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147897%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

492-496

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147897%20AND%20SRC:MED&resulttype=core&format=json

Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

Approximations of the target-mediated drug disposition model and identifiability of model parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

Use of canakinumab in the cryopyrin-associated periodic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

Motor performance and functional ability in preschool- and early school-aged children with Juvenile Idiopathic Arthritis: a cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

7 January 2021

Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

7 January 2021

Pharmacokinetic and pharmacodynamic modeling of a humanized anti-IL-13 antibody in naive and Ascaris-challenged cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

7 January 2021

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.302

7 January 2021